AlphAIalphai — Financial news for AI agents
BenzingaSEP 173 min read$PYPD

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference - PolyPid (NASDAQ:PYPD)

PETACH TIKVA, Israel, Sept. 17, 2025 ( GLOBE NEWSWIRE ) -- PolyPid Ltd. PYPD ( "PolyPid" or the "Company" ) , a late-stage biopharma company aiming to improve surgical outcomes, today announced that management will be presenting at the Lytham Partners Fall 2025 Virtual Investor Conference on ...

Original reporting
Benzinga · Globe Newswire
Published Sep 17, 2025, 12:44 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 17, 2025, 1:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference - PolyPid (NASDAQ:PYPD) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$PYPDNeutralMed
01

Why it matters

The upcoming presentation could enhance investor confidence and visibility, potentially leading to short-term stock appreciation.

02

Market read

The event is relevant for investors interested in biotech and healthcare sectors, with potential short-term trading opportunities.

03

What to watch

Market reaction may be influenced by broader biotech sector developments or macroeconomic factors unrelated to the conference.

Timing: short-term (next 1-2 weeks)

Background

PolyPid is a late-stage biopharma company focusing on surgical infection prevention, actively engaging with investors through conferences.

Company-level read

Ticker impact

$PYPDNeutralMedium confidence
Context

The news pertains directly to PolyPid's upcoming investor conference presentation, which could influence investor sentiment and stock performance.

Expected impact

Potential short-term increase in stock price due to heightened investor interest, but limited long-term impact without additional catalysts.

Evidence & confidence

While investor conferences can boost visibility, the direct impact on stock price depends on the content of the presentation and market conditions. The current sentiment score indicates a cautious outlook.

Market effects

Sector

Positive sentiment in the Life Sciences sector, especially among biotech and biopharma companies involved in innovative surgical solutions.

Regional

Limited regional impact; primarily affects investors and markets with significant biotech activity in Israel and the US.

Global

Moderate; reflects ongoing investor interest in biotech innovations and healthcare advancements.

Counterpoint

What could challenge this read

The conference presentation may be a routine event with minimal impact; any positive movement could be short-lived and driven by broader market trends.

Key entities

  • Company
    PolyPid Ltd.

    A biopharmaceutical company specializing in infection prevention solutions for surgical procedures.

  • Organization
    Lytham Partners

    An investor relations firm hosting the fall 2025 virtual investor conference.

  • Event
    ROTH Healthcare Opportunities Conference

    An annual conference focusing on healthcare investment opportunities.

Read at source← All news

Related articles

AUG 19
HighAI 8/10

PolyPid (PYPD) Q2 2026 Earnings Call Transcript

PolyPid (PYPD) reported Q2 2026 milestones: FDA accepted its NDA for D-PLEX100 with Priority Review, setting a PDUFA goal date of November 28, 2026. The company also signed a $320M+ commercialization deal with Azurity Pharmaceuticals for the U.S. and Canada, including upfront payments, milestones, and royalties. PolyPid plans to submit an MAA to the EMA in Q3 2026 and expects a U.S. launch in early 2027.

yahoo.com3 min
AUG 14
$PYPDMed

PolyPid Ltd. Q2 2026 Earnings Call Summary

PolyPid said the FDA accepted its D-PLEX100 NDA with Priority Review and no filing issues, targeting a PDUFA date of Nov. 28, 2026. It signed an exclusive U.S. and Canada commercialization deal with Azurity, including upfront and tiered royalties plus a transfer price for retained manufacturing units. PolyPid expects a U.S. launch in early 2027 and $30M in milestone payments.

yahoo.com6 min
AUG 12
$PYPDHighAI 9/10

PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid Ltd. (Nasdaq: PYPD) said the FDA accepted its D-PLEX100 NDA for priority review for preventing surgical site infections in abdominal colorectal surgery, with a PDUFA goal date of Nov. 28, 2026. PolyPid entered an exclusive U.S. and Canada commercialization partnership with Azurity, receiving $30 million upfront and near-term milestones, plus tiered mid-teen to mid-twenties royalties. Q2 2026 net loss was $7.8M.

finanznachrichten.de7 min
AUG 12
$PYPDHigh

PolyPid Ltd. (PYPD): Financial results for Q2 2026

PolyPid Ltd. (PYPD) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results FDA Accepted D-PLEX₁₀₀ NDA with Priority Review; PDUFA Goal Date of November 28, 2026, Approximately One Quarter Ahead of Previously Communicated Guidance Exclusive U.S. and Canada Co

SEC EDGAR 6-K2 min
JUL 29
$PYPDMedAI 8/10

PolyPid Ltd.: PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX100

PolyPid (Nasdaq: PYPD) said the FDA accepted its NDA for D-PLEX100 to prevent surgical site infections in abdominal colorectal surgery and granted Priority Review. The PDUFA target action date is Nov. 28, 2026. FDA found no filing review issues. Acceptance triggers a $15 million milestone from Azurity, completing $30 million in upfront and near-term milestones.

finanznachrichten.de2 min
JUL 24
$PYPDMedAI 8/10

Antibacterial Drug Partnership Accelerates PolyPid Commercial Path

PolyPid Ltd. (PYPD) said it signed an exclusive commercialization deal with Azurity Pharmaceuticals for D-PLEX100 to prevent abdominal surgical site infections in the U.S. and Canada. PolyPid gets $15M upfront, $15M on FDA NDA acceptance, and up to $300M in milestones. Deal follows Phase 3 SHIELD II results; U.S. launch targeted Q1 2027. Analysts at Roth and H.C. Wainwright set Buy ratings and $9 and $13 targets.

streetwisereports.com7 min